Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Elodie Duray"'
Autor:
Margaux Lejeune, Murat Cem Köse, Mégane Jassin, Marie-Jia Gou, Amaury Herbet, Elodie Duray, Gaël Cobraiville, Jacques Foguenne, Didier Boquet, André Gothot, Yves Beguin, Marianne Fillet, Jo Caers
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e901 (2023)
Despite the recent introduction of next-generation immunotherapeutic agents, multiple myeloma (MM) remains incurable. New strategies targeting MM-specific antigens may result in a more effective therapy by preventing antigen escape, clonal evolution,
Externí odkaz:
https://doaj.org/article/941162fc8eb943a5ac5f70af1a269293
Autor:
Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D’Huyvetter, Mireille Dumoulin, Jo Caers
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-13 (2021)
Abstract Background Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain anti
Externí odkaz:
https://doaj.org/article/6b141013e0604fe3b0f374aa12371db3
Autor:
Jo Caers, Elodie Duray, Louise Vrancken, Guillaume Marcion, Valentina Bocuzzi, Kim De Veirman, Ahmet Krasniqi, Margaux Lejeune, Nadia Withofs, Nick Devoogdt, Mireille Dumoulin, Amelie Eriksson Karlström, Matthias D’Huyvetter
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a bro
Externí odkaz:
https://doaj.org/article/be1525215bad43ffa1f35ebe39a6b115
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Bispecific antibodies (BsAbs) are designed to recognize and bind to two different antigens or epitopes. In the last few decades, BsAbs have been developed within the context of cancer therapies and in particular for the treatment of hematologic B-cel
Externí odkaz:
https://doaj.org/article/ded43acfceb54650979aededfeaa99c5
Autor:
Joséphine Muller, Arnold Bolomsky, Sophie Dubois, Elodie Duray, Kathrin Stangelberger, Erwan Plougonven, Margaux Lejeune, Angélique Léonard, Caroline Marty, Ute Hempel, Frédéric Baron, Yves Beguin, Martine Cohen-Solal, Heinz Ludwig, Roy Heusschen, Jo Caers
Publikováno v:
Haematologica, Vol 103, Iss 8 (2018)
Multiple myeloma bone disease is characterized by an uncoupling of bone remodeling in the multiple myeloma microenvironment, resulting in the development of lytic bone lesions. Most myeloma patients suffer from these bone lesions, which not only caus
Externí odkaz:
https://doaj.org/article/43a3ed5b0efb4ca4a7bad8fc9e723694
Autor:
Yoline Lauwers, Yves Beguin, Mireille Dumoulin, Jo Caers, Margaux Lejeune, Frédéric Baron, Ahmet Krasniqi, Matthias D'Huyvetter, Yong Juan Zhao, Nick Devoogdt, Elodie Duray
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-13 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-13 (2021)
Background Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD38 single-domain antibodies (s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04afc6e1c71e02279c98dd68f048a746
https://doi.org/10.1186/s13045-021-01171-6
https://doi.org/10.1186/s13045-021-01171-6
Autor:
Murat Cem Köse, Margaux Lejeune, Marie Jia Gou, Elodie Duray, Gael Cobraiville, Jacques Foguenne, Andre Gothot, Yves Beguin, Mariane Fillet, Jo Caers
Publikováno v:
Blood. 140:4219-4219
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::affb190189312454277bf2ddf06f27de
https://doi.org/10.1182/blood-2022-156300
https://doi.org/10.1182/blood-2022-156300
Autor:
Elodie Duray, Margaux Lejeune, Béatrice Clémenceau, Yves Beguin, Jo Caers, Matthias Peipp, Frédéric Baron
Publikováno v:
Cancers
Volume 13
Issue 12
Cancers, 2021, 13 (12), pp.3072. ⟨10.3390/cancers13123072⟩
Cancers, MDPI, 2021, 13 (12), pp.3072. ⟨10.3390/cancers13123072⟩
Cancers, Vol 13, Iss 3072, p 3072 (2021)
Volume 13
Issue 12
Cancers, 2021, 13 (12), pp.3072. ⟨10.3390/cancers13123072⟩
Cancers, MDPI, 2021, 13 (12), pp.3072. ⟨10.3390/cancers13123072⟩
Cancers, Vol 13, Iss 3072, p 3072 (2021)
Simple Summary We tracked the cytotoxic potential of NK cells towards multiple myeloma cells in daratumumab-mediated antibody-dependent cellular cytotoxicity assays. These cytotoxicity levels could be directly correlated to the expression of the targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f581bee62647f0f31c29367a3d1dd0b
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S28
Background Theranostic agents include molecules with a combined diagnostic and therapeutic capability and nanobodies (Nbs) are increasingly used in this field. Nbs are single-domain antigen-binding fragments that are derived from Camelidae heavy-chai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab513dcadcbd83c345f8a49ce5f3ab4c
https://doi.org/10.1016/s2152-2650(21)02118-2
https://doi.org/10.1016/s2152-2650(21)02118-2
Autor:
Frédéric Baron, Arnold Bolomsky, Elodie Duray, Jo Caers, Roy Heusschen, Joséphine Muller, Heinz Ludwig, Yves Beguin, Nadia Withofs, Eline Menu
Publikováno v:
Leukemia & Lymphoma. 59:14-28
Multiple myeloma (MM) bone disease is a major cause of morbidity and mortality in MM patients and persists even in patients in remission. This bone disease is caused by an uncoupling of bone remodeling, with increased osteoclast and decreased osteobl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::183515d0fc0c6aa5876c01201607f1c2
https://doi.org/10.1080/10428194.2017.1323272
https://doi.org/10.1080/10428194.2017.1323272